Hikma Pharmaceuticals (LON:HIK) Shares Pass Above 200-Day Moving Average – Time to Sell?

Hikma Pharmaceuticals PLC (LON:HIK)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,460.77 and traded as high as GBX 1,494. Hikma Pharmaceuticals shares last traded at GBX 1,474.39, with a volume of 508,198 shares.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Jefferies Financial Group upped their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of GBX 2,128.

Hikma Pharmaceuticals Stock Down 0.2%

The stock has a market capitalization of £3.17 billion, a PE ratio of 8.15, a price-to-earnings-growth ratio of 2.38 and a beta of 0.64. The company has a debt-to-equity ratio of 63.59, a current ratio of 1.82 and a quick ratio of 1.27. The business’s fifty day moving average price is GBX 1,361 and its two-hundred day moving average price is GBX 1,460.77.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.